Sanofi diabetes combo meets Phase III goal
Sanofi’s combination type 2 diabetes drug LixiLan has met its primary endpoint in its first Phase III trial.
Read MoreAuthor: George Underwood
Sanofi and Regeneron look to break into immunotherapy
Sanofi will extend its fruitful partnership with Regeneron into the promising area of cancer immunotherapies with an investment worth up to $2.17 billion.
Read MoreSanofi dengue vaccine shows promise in older children
Sanofi’s dengue vaccine candidate protects more than two-thirds of children aged 9 and older, but could increase the risk of hospitalisation in younger children, according to a new analysis.
Read MoreAccelerated EU review for Takeda multiple myeloma drug
The EMA has granted accelerated assessment for Takeda’s investigational multiple myeloma drug ixazomib.
Read MorePositive results for Alzheimer’s app
A new app could help prevent the onset of Alzheimer’s disease, according to research unveiled last week.
Read More- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
- Pulsesight reports positive phase 1 data for PST‑611 in dry AMD
- UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
